European Academy of Dermatology and Venereology

SUNSHINE and SUNRISE trials showed superior efficacy over the placebo.

Taking a deep dive into alopecia areata allows for a better understanding of the cells that are responsible for disease development.

Medical experts use common set of criteria to diagnose disease.

Study data was presented at EADV 2022 regarding socioeconomic status related to HS.

The relationship between transplant patients and basal cell carcinoma was discussed at EADV Congress 2022 in Milan, Italy.

TMB-001 showed positive results in the reduction of congenital ichthyosis severity in a phase 2b CONTROL study.

New sticky tape study can help predict onset of pediatric atopic eczema in babies.

The relationship between mental health and psoriasis was discussed at EADV Congress 2022 in Milan, Italy.

Arcutis to present data from topical roflumilast clinical program at EADV 2022 Congress.

Abstracts will include updates on treatment for psoriatic arthritis, psoriasis, atopic dermatitis, and more.

The new data examines delivery system efficacy of either 1 secukinumab 300-mg dose in an autoinjector vs 2 doses of secukinumab 150-mg 1 mL pre-filled syringes.

A new study shows a possible association between fasting and skin improvement in psoriasis patients.

New study data presented at EADV demonstrated an association between COVID-19 severity in male patients and the sex hormone androgen.

Research presented at the EADV Spring Symposium 2021 investigated the link between gut bacteria and skin inflammation.

According to one expert at the 29th European Academy of Dermatology and Venereology Virtual Congress, trichoscopy (a dermoscopy-based diagnostic method) not only helps diagnose hair disorders and monitor treatment but also predicts treatment efficacy.

Dermatofibrosarcoma is a common, but unusual locally aggressive cutaneous tumor. Its characteristic tentacle can grow into surrounding fat, muscle and even bone. For dermatologists this means that understanding treatment options is a priority, says a physician reporting from EADV 2018.

Is it just a “spot” or precancerous lesion? Two physicians debate how best to treat actinic keratosis in a talk given at EADV last week.

There are many non-surgical treatments for basal cell carcinomas, but a physician reporting at EADV last week said new treatments should be compared against surgery, which has the highest cure rate and lowest rate of recurrence.

A pregnancy-associated melanoma (PAM) prognosis does not appear to be worse than melanoma in non-pregnant controls, researchers reported at EADV. Nonetheless, measures should be taken to protect the fetus in the treatment and imaging of PAM.

EADV report summarizes the latest advances in laser technology for tattoo removal.

Life-threatening emergency cases may be rare, but they can be complex. At EADV this week, experts review cases physicians should be aware of.

A study presented at EADV in Paris today showed that dupilumab met its primary endpoints in a phase three study of adolescents with moderate-to-severe atopic dermatitis.

EADV report shows that two JAK inhibitors reverses alopecia areata in some patients.

Potential new treatment with targeted monoclonal antibodies offers new hope for cutaneous lymphoma patients.

Clinicians are more likely to correctly identify the lesions’ underlying cause with careful observation rather than with several lab tests.

Patients who achieve complete skin clearance of psoriasis experience a noticeable difference in quality of life and work productivity.

With immunotherapy as a key treatment for melanoma, dermatologists should be prepared to treat its cutaneous side effects and refer for adrenal sufficiency, uveitis, thyroid disease and other non-cutaneous side effects.

Checkpoint inhibitors have clearly changed the prognosis of melanoma, yet the search for evidence-based answers to these and other questions regarding their use continues, experts report at EADV this week.

Patients who undergo treatment with ixekizumab experience greater nail psoriasis improvement than individuals treated with ustekinumab.

Risankizumab performed better in treating psoriasis that appears on the nails, hands and feet, palms and scalp sores.